The LEADER trial (liraglutide), SUSTAIN-6 (semaglutide), and EXSCEL (exenatide) studies, which collectively followed thousands of patients for several years, did not report significant increases in fracture rates compared to placebo groups
Implications for Practice Due to the established connection between GLP-1 agonists and DR, optometrists should err on the side of caution and be in contact with primary care physicians on whether GLP-1/gastric inhibitory polypeptide (GIP) agonists should be prescribed in patients who have existing DR
For some people, appetite-related changes may begin within the first few weeks of treatment, but the exact timeline varies from person to person
Two weeks ago the FDA's Endocrinologic and Metabolic Drugs Advisory Committee reviewed the trials and rejected recommendations from critics for new restrictions on their use, but they did say that information from the two clinical trials should be added to the drugs' labels
Choose BPC-157 if: Your injury is localized and you want targeted effects at a specific site
Regardless, we emphasize that PUF-3 and PUF-11 are the long-sought missing self-renewal regulators